Matricellular proteins osteopontin and osteonectin/SPARC in pancreatic carcinoma

SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients

(2014) Neil Desai et al.   Translational Oncology

Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma

(2010) Tine S. Mantoni et al.   CANCER BIOLOGY & THERAPY

Osteopontin but not osteonectin favors the metastatic growth of pancreatic cancer cell lines

(2010) Maria Zhivkova-Galunska et al.   CANCER BIOLOGY & THERAPY

Stromal Depletion Goes on Trial in Pancreatic Cancer

(2010) K. Garber   JNCI-Journal of the National Cancer Institute

Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma

(2009) S. A. Arnold et al.   Disease Models & Mechanisms

Expression of a prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma

(2009) Jennifer Sullivan et al.   SURGERY

SPARC: a matricellular regulator of tumorigenesis

(2009) Shanna A. Arnold et al.   Journal of Cell Communication and Signaling

The role of SPARC in extracellular matrix assembly

(2009) Amy D. Bradshaw   Journal of Cell Communication and Signaling

Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status

(2008) Neil P. Desai et al.   ANTI-CANCER DRUGS

Osteopontin as a target for cancer therapy

(2008) Nicholas IF Johnston   Frontiers in Bioscience-Landmark

Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas

(2008) Seung-Mo Hong et al.   MODERN PATHOLOGY